# Tao Fu

> Tao Fu is a Series A investor at Attovia Therapeutics backing Medical. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: Attovia Therapeutics
- Location: San Francisco, United States
- Total investments: 3
- Last investment: Apr 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/taofu/

Tao Fu is a Series A investor at Attovia Therapeutics in San Francisco focused on Medical and Health Care. Tao Fu is the Founder and Chief Executive Officer of Attovia Therapeutics. He previously worked at Zai Lab as a President and Chief Operating Officer. Tao Fu attended Vanderbilt University - Owen Graduate School of Management.

## Contacts

5 contacts available for Tao Fu: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/tao-fu?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Biotechnology | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Series C | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Attovia Therapeutics | Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $90M | Series C | Apr 15, 2025 |  |
| Attovia Therapeutics | Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $105M | Series B | May 09, 2024 |  |
| Attovia Therapeutics | Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $60M | Series A | Jun 20, 2023 |  |

3 of 3 investments shown.

## Co-investors
- [Illumina Ventures](https://shizune.co/investors/profile/illumina-ventures) — VC Fund, 3 deals together
- [venBio Partners](https://shizune.co/investors/profile/venbio) — VC Fund, 3 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 2 deals together
- [Goldman Sachs Asset Management](https://shizune.co/investors/profile/goldman-sachs-asset-management) — VC Fund, 2 deals together
- [Marshall Wace](https://shizune.co/investors/profile/marshall-wace) — VC Fund, 2 deals together
- [Nextech Ventures](https://shizune.co/investors/profile/nextech-ventures) — VC Fund, 2 deals together

## About Attovia Therapeutics

VC Fund · Fremont, United States

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated.

1 contacts available at Attovia Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Tao Fu | Chief Executive Officer and Founder | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Tao Fu invest in?

Tao Fu invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Tao Fu?

Public channels for Tao Fu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Tao Fu last invest?

The most recent investment recorded for Tao Fu closed in Apr 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co